New inhaled drug for lung scarring enters early human testing
Disease control
Completed
This early-stage trial is testing an inhaled form of nintedanib (called MNKD-201) in 24 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. The study aims to see if the drug is safe and tolerable when breathed in, and how the body processes it. Partic…
Phase: PHASE1 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC